Brief: Inozyme Pharma Announces Updates On Global Development Strategy Of INZ-701 For Treatment Of ENPP1 Deficiency

Inozyme Pharma

26/07/2023 12:45

July 26 (Reuters) - Inozyme Pharma Inc  INZY.O :
    * INOZYME PHARMA ANNOUNCES UPDATES ON GLOBAL DEVELOPMENT
STRATEGY
OF INZ-701 FOR THE TREATMENT OF ENPP1 DEFICIENCY
    * ENERGY-3 PIVOTAL TRIAL IN PEDIATRIC PATIENTS EXPECTED TO
INITIATE IN OCTOBER 2023
    * INOZYME - CHANGE IN PLASMA PYROPHOSPHATE AS PRIMARY
ENDPOINT IN
U.S. AND CO-PRIMARY ENDPOINT IN EU FOR PLANNED ENERGY-3 PIVOTAL
TRIAL IN PATIENTS
    * UPDATED CASH RUNWAY EXPECTED TO FUND CASH FLOW
REQUIREMENTS INTO
Q1 2025
    * COMPANY EXPECTS TO COMMERCIALLY LAUNCH INZ-701 FOR INFANT
AND
PEDIATRIC PATIENTS AS EARLY AS SECOND HALF OF 2026
    * TOPLINE DATA EXPECTED TO BE REPORTED IN MID-2025

Source text for Eikon:  ID:nGNXwhMhk 
Further company coverage:  INZY.O 

 ((Reuters.Briefs@thomsonreuters.com;))